rs1192131078
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Recently, the rs61752561 SNP (Asp84Asn substitution) in exon 3 of the kallikrein-related peptidase 3 (<i>KLK3</i>) gene encoding prostate-specific antigen (PSA) was reported to be strongly associated with PCa risk (<i>P</i> = 2.3 × 10<sup>-8</sup>).
|
30538125 |
2019 |
rs369223448
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Furthermore, XB130 knockdown hindered transition of G1 to S phase in prostate cancer cell line DU145 and LNCap, which might contribute to the inhibition of cellular proliferation.
|
27509056 |
2016 |
rs781327047
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Furthermore, XB130 knockdown hindered transition of G1 to S phase in prostate cancer cell line DU145 and LNCap, which might contribute to the inhibition of cellular proliferation.
|
27509056 |
2016 |
rs141576693
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Based on these results, we concluded that the p21 C70T polymorphism is associated with decreased risk of prostate cancer in Slovak men.
|
23292332 |
2013 |
rs538660698
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Racial differences in prediction of time to prostate cancer diagnosis in a prospective screening cohort of high-risk men: effect of TMPRSS2 Met160Val.
|
20735386 |
2011 |
rs62113214
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We did not observe a strong association with the KLK3 variant, reported in previous studies to confer risk for prostate cancer (rs2735839; P = 0.20) but did observe three highly correlated SNPs (rs17632542, rs62113212 and rs62113214) associated with prostate cancer [P = 3.41 × 10(-4), per-allele trend odds ratio (OR) = 0.77, 95% CI = 0.67-0.89].
|
21318478 |
2011 |
rs765521022
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A link between elevated IL6 and up-regulated S100P in androgen-refractory and metastatic PCa is postulated.
|
15474988 |
2005 |
rs1450063773
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Three prostate cancer-derived p53 mutants (F134L, M237L, R273H) were introduced into LNCaP prostate cancer cells and stable transfectants established.
|
14587098 |
2003 |
rs61752561
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The rs61752561 SNP appears to have a potential role in PCa pathogenesis by changing the glycosylation, protein stability, and PSA activity and may also affect the clinically measured F/T PSA ratio.
|
30538125 |
2019 |
rs1058205
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The overall results indicated that polymorphism T>C of rs1058</span>205 was associated with decreased risk of PCa</span> (allele contrast: OR = 0.75, 95% CI = 0.64-0.88, <i>P</i><sub>heterogeneity</sub> < 0.001; homozygote comparison: OR = 0.58, 95% CI = 0.42-0.81, <i>P</i><sub>heterogeneity</sub> < 0.001), particularly in Caucasian population (allele contrast: OR = 0.77, 95% CI = 0.65-0.91, <i>P</i><sub>heterogeneity</sub> < 0.001; homozygote comparison: OR = 0.58, 95% CI = 0.41-0.82, <i>P</i><sub>heterogeneity</sub> < 0.001).
|
30413614 |
2018 |
rs1058205
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The frequency of the TC genotype of rs1058205 in the PCa group was significantly lower than that in the control group (P = 0.049).
|
28272245 |
2017 |
rs61752561
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The rs61752561 in KLK3 and rs2735839 in the KLK2-KLK3 intergenic region were strongly associated with prostate cancer-specific survival, and rs10486567 in the 7JAZF1 gene were associated with biochemical recurrence.
|
20460480 |
2010 |
rs746367915
|
|
|
0.020 |
GeneticVariation |
BEFREE |
This exploratory analysis in prostate cancer patients revealed the W allele of the KLK2 R250W SNP to be less likely associated with low GS morphology.
|
21178268 |
2010 |
rs746367915
|
|
|
0.020 |
GeneticVariation |
BEFREE |
An association of a single nucleotide polymorphism (SNP) of the KLK2 gene (rs198977; c.748C>T; R250W) with risk for developing prostate cancer has been observed.
|
21178268 |
2010 |
rs746367915
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Our results suggest that the C allele of the functional C748T polymorphism of KLK2 may increase the risk of PCa.
|
15643194 |
2005 |
rs149709822
|
|
|
0.040 |
GeneticVariation |
BEFREE |
This study tested the interactions of VDR (CDX2, FokI) and SRD5A2 (V89L, A49T) polymorphisms, and their associations with prostate cancer.
|
18483391 |
2008 |
rs149709822
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Cytosine-adenine-guanine repeat length of the androgen receptor gene and the A49T and V89L polymorphisms of the 5 alpha-reductase (SRD5A2) gene have been associated with prostate cancer.
|
12210487 |
2002 |
rs149709822
|
|
|
0.040 |
GeneticVariation |
BEFREE |
The SRD5A2 V89L and A49T polymorphisms were, however, not associated with altered prostate cancer risk.
|
12042668 |
2002 |
rs149709822
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Conversely, no association was observed between prostate carcinoma risk and the other polymorphisms studied as follow: the CAG repeat in exon 1 of AR, the (TA)n dinucleotide repeat polymorphism in the 3' untranslated region, and the A49T or V89L substitutions in SDR5A2, the single base pair (bp) (a T to C transition) polymorphism that creates an additional Sp1-type (CCACC box) promoter site in CYP17.
|
11571725 |
2001 |
rs266882
|
|
|
0.050 |
GeneticVariation |
BEFREE |
In addition, no association was observed between polymorphism A>G of rs266882 and risk of PCa.
|
30413614 |
2018 |
rs266882
|
|
|
0.050 |
GeneticVariation |
BEFREE |
We evaluated the impact of genetic variation in the prostate-specific antigen (PSA) gene (rs266882) on serum PSA levels in healthy men as well as risk factors for benign prostate hypertrophy (BPH) and prostate cancer.
|
23315126 |
2013 |
rs266882
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Association of G/A polymorphism, rs266882, in AREI region of the prostate-specific antigen gene with prostate cancer risk and clinicopathological features.
|
23235975 |
2012 |
rs266882
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Meta-analysis of 12 studies of rs266882 and overall p</span>rostate cancer risk was null.
|
18827812 |
2008 |
rs266882
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Men homozygous or heterozygous for the G/G (rs925013/rs266882) haplotype were at higher risk of prostate cancer than men homozygous for the A/A haplotype (odds ratio, 1.3; 95% CI, 1.1-1.7; P = 0.009).
|
16775173 |
2006 |
rs62113212
|
|
T |
0.710 |
GeneticVariation |
GWASCAT |
Two susceptibility loci identified for prostate cancer aggressiveness.
|
25939597 |
2015 |